We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 419.00 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 420.50 | 422.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 89.54M | -184.16M | -1.7479 | -2.41 | 441.46M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:17:32 | O | 8,000 | 419.955 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/12/2024 | 07:00 | UK RNS | Oxford Biomedica PLC Total Voting Rights |
| 22/11/2024 | 14:56 | UK RNS | Oxford Biomedica PLC Grant of options |
| 18/11/2024 | 07:00 | UK RNS | Oxford Biomedica PLC Board Changes |
| 15/11/2024 | 07:00 | UK RNS | Oxford Biomedica PLC OXB to present at Jefferies Healthcare Conference |
| 05/11/2024 | 14:23 | UK RNS | Oxford Biomedica PLC Grant of options |
| 04/11/2024 | 10:56 | UK RNS | Oxford Biomedica PLC Holding(s) in Company |
| 01/11/2024 | 07:00 | UK RNS | Oxford Biomedica PLC Total Voting Rights |
| 31/10/2024 | 07:00 | UK RNS | Oxford Biomedica PLC Holding(s) in Company |
| 21/10/2024 | 08:47 | UK RNS | Oxford Biomedica PLC Block Listing Application |
| 04/10/2024 | 14:25 | UK RNS | Oxford Biomedica PLC Grant of Options |
Oxford Biomedica (OXB) Share Charts1 Year Oxford Biomedica Chart |
|
1 Month Oxford Biomedica Chart |
Intraday Oxford Biomedica Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/12/2024 | 12:08 | OXB. One owner, FSH Excellent conditionwith ejector seat | 9,443 |
| 13/3/2024 | 11:08 | Where we going | 945 |
| 13/2/2024 | 12:39 | Oxford Biomedica | 2,118 |
| 14/9/2023 | 09:29 | Open-minded posters thread | 576 |
| 26/4/2023 | 14:56 | OXB - sense and sensibility | 479 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 07:15:05 | 419.96 | 8,000 | 33,596.40 | O |
| 2024-12-30 17:15:00 | 419.51 | 6,488 | 27,218.00 | O |
| 2024-12-30 16:35:27 | 419.00 | 11,662 | 48,863.78 | UT |
| 2024-12-30 16:29:17 | 420.85 | 71 | 298.80 | O |
| 2024-12-30 16:27:02 | 420.76 | 662 | 2,785.40 | O |
| Top Posts |
|---|
Posted at 16/12/2024 20:39 by harry s truman Xoptimist,I think it depends on how you value the company, which I appreciate is stating the obvious. We do know that the "average" CDMO should trade on more than 5x sales and an average CDMO isn't one which owns the patents on the LentiVector which is key to one approved treatment and a whole bunch in late trials. What do we currently trade on with our market cap today of c£450m? A little over 3x. What if Novo simply accept that OXB is worth a lot more than its market cap and realise that there are enough shares in very few hands to stop a cheap bid - which has never happened during much worse times? Today Samsung Bio (a very specialised CDMO) trades on 16.29x sales and nobody complains. In a couple of weeks we go into a year where Frank said the sales would be better than +35% on this year. That basically means £180m but it might be better. What if our major shareholders say that they want a bid premium on top of a fair valuation which the market price doesn't reflect? I'd agree wholeheartedly that we would be in the hands of others, but I seem to remember that 13 holders have 70% of OXB. Admittedly one of those is Novo with 12% but most of the others against and it's still no - which is (I suspect) what kept the p/e wolves from our door when things were much worse. 5.5x 2025 sales is probably £10 per share and what if our major shareholders say they aren't prepared to sell for sector average and want compensating with a better valuation and bid premium? I of course don't know and don't pretend to. I agree with Dom's point in that Novo are in the happy position of being able to bid billions without visiting a bank for a loan or visiting a city firm for a placing / fundraising, so where would the leak come from? Mentioned here before that I have no evidence other than circumstantial, but:- The Novo Holdings boss has said they will buy specially selected bio service companies (like OXB which they already thought worth buying 12% of). OXB has been extremely quiet and for the first time I can remember not a single insider has bought a share in the year (since Novo bid for Catalent). Yes Catalent shareholders overwhelming accepted a low bid premium from Novo but they also knew that they were on a sticky wicket without Novo's money - which does sort of beg the question of how Novo plan to make a business success of that other than by simply throwing more money at it? There are two sides to this, but let's forget about Catalent for a minute and say that Novo harboured desires of entering the Cell and Gene Therapy sector via OXB, then how do they make that work for them better than it has worked / is working for OXB? Surely the answer is simply scale, and on a scale which OXB wouldn't be able to afford alone anytime soon? Flip back to Catalent and (if you believe the official version) then Novo only wanted Catalent for the 3 pen injectable sites which solve a supply shortage for their mega-selling weight loss drug. Why didn't Novo just bid this notional $11bn for the 3 factories they wanted in a simple transaction / trade sale which happens a lot in the pharma industry and save themselves a lot of trouble? I think there are two possible answers to that, with one being that Catalent said a firm no to them cherry picking, making it all or northing, or... Novo thought, 2 birds with one stone - we buy the lot, sell the pen injectables to Nordisk then merge OXB with the Catalent C> / C> capable plants. Maybe the rest they will keep to run as a big CDMO or plan to slowly sell off the individual sites as and when that makes good business sense. So yes I am guessing, but there is some supporting evidence behind it - even though it is circumstantial. If Novo Holdings are keen to diversify into CDMO and are sold on those future forecasts for C> CDMO market size, then there is some logic in the business case here. |
Posted at 10/12/2024 11:18 by harry s truman Time will tell - both with the takeover hypothesis and the price, but I'm inclined to the idea of the former mainly because the boss of Novo Holdings had previously indicated a plan to buy up companies like OXB.Re the share price, then there's no point arguing what the market thinks it is worth at the moment. Myself though, I think a much more important figure is what the majority of our major shareholders think OXB is worth. The market is simply looking at sales and profits, but some of OXB's IP and knowhow is incredibly valuable and not in the price. At the moment the market price isn't representative (for various reasons we talk about a lot) but if the Novartis work alone is worth £25m per year to us (and I think it is about that) then just that should be worth about £1.30 / £1.40 per share - and wasn't it Novartis + 36 more customers we had at the last count? OK the others are not as large, but even so? I also think you have to be careful about the price of the shares which OXB were willing to place for IM as IM had previously sold us something quite valuable for a very low valuation and accepted full payment in shares at twice the market price. So that final placing was a fair deal for them and hasn't been offered to anyone else. I've listed the shareholdings before, but the top 3 own 30% and the top 13 something like 70%. A lot of them have held for a very long time and they know what OXB is worth. Unless they are distressed then how would an opportunistic bid work? |
Posted at 07/12/2024 16:38 by harry s truman Aside from the obvious you mean?IM merged ABL Europe into OXB to get a part of future business which they couldn't compete for alone via a shareholding in OXB which they took as full payment. Amazing deal for OXB but driven by what OXB had and what ABL didn't have. As Seb explained, they would never have been able to catch up with the vector tech on their own and when the analyst asked "so it was a case of if you can't beat them join them?" he replied yes. Would they have imagined OXB then being bought out? Well it must have been considered as a risk. If it's enough money to compensate them for selling those expected future OXB profits now then I would imagine they would be ok with it. If not then what are they going to do? It's a risk we all take. If there is no bid coming then I would expect them to be very pleased with c£180m in sales next year and a profit (as will I). Something is going on and your guess is as good as mine. OXB went quiet 6 months before the ABL deal was announced and no insiders bought shares between the full year results and that deal announcement (following which a lot of them immediately bought shares). Nobody could have guessed that deal was on from what was in the public domain before it happened. Investment detectives might have spotted that Seb was an adviser to IM, but how would you guess more beforehand? Today is a bit different as there seem to be a lot of clues out there indicating that Novo could make good use of OXB's skillset in their newly acquired C> arm of Catalent. Is it true or is it just coincidence? As I wrote the other day, if there is something in this then following FTC approval there is no point in Novo waiting. They have just spent 16.5bn on something which they will want to see come good. Next step is waiting to see what the FTC say. |
Posted at 04/12/2024 10:17 by harry s truman 2 days to the deadline for the EU anti-trust decision on Novo Catalent.Meanwhile Novo on a charm offensive with Catalent's existing US customers, offering them contract extensions by way of reassurance. The US FTC decision is supposed to be before the end of the year. Catalent seem very happy to be taken over and have their recent wobbles rendered irrelevant by Novo's very deep pockets. Catalent's shareholders 99% in favour rather than the other option of Catalent staying single. Novo is reassuring Catalent's customers. US stock market seems to think that the deal will go through at the offered price, which to me is a reminder of the bookies all knowing Trump would win whilst the world's press were busy thinking up reasons of why he wouldn't. Personally (usual wealth warnings here / amateur forecasting alert) I think the deal will pass both regulators without issue. Shortly after that Novo Holdings will sell 3 factories to Novo Nordisk and become owner managers of the rest (a very large global CDMO which needs a boost). If that happens then we soon (relative term) will find out if there is a connection between Novo Holdings owning 12% of OXB and not a single OXB insider buying shares since Novo Holdings bid for Catalent. As mentioned previously many times, there's perhaps a healthy dose here of me connecting random events which look connected but are just circumstantial. However, it does make sense to me that if Novo Holdings are looking to make Catalent a core asset (and they are) then they can't just leave it as is. There must be a plan (which is always easier to come up with when sat on a cash mountain). The Novo Holdings non-exec director on our board will know much better than us what OXB can do. But he will also know that for OXB to grow (even at better than 35%) will take years because that's how long it takes to fund and kit out new facilities. Money isn't an issue for NH (unless having too much of it is a problem) but in weeks they are likely to own 4 cell & gene therapy factories and a blank canvas of the brand new and empty former UK government Vaccine Manufacturing & Innovation Centre (VMIC) in Oxford, on OXB's doorstep. I couldn't give you the odds here of this coming true, but if following Catalent approval Novo Holdings bid for the 88% of OXB which they don't own, then something which would have taken OXB 20 years or longer, can be done very quickly. Novo could roll out OXB's tech / knowhow and experience into the existing 4 Catalent C> factories, whilst OXB get a 6th site at Oxford to expand into. OXB shareholders get paid off on acceptable terms which Frank will recommend. In exchange for that money Novo Holdings quickly own the biggest / best C> CDMO. Stranger things have happened at Christmas. |
Posted at 28/11/2024 10:33 by harry s truman There are quite a few OXB partners with both seemingly excellent prospects and very battered (aka tempting) share prices. I realise some of this (well quite a bit of it) is down to the disastrous worldwide overreaction to covid, but there's also plainly the issue of too many similar companies chasing the same targets - and this is especially true in CAR-T.I've mentioned before on here that for various reasons I'm really quite happy with OXB only selling the shovels these days, rather than actually digging for the gold. Out of our c40 partners at the moment, I would guess that a good half of them are working in the current vogue of CAR-T. This isn't a problem for OXB as we will sell our services to them all, but it's unrealistic to assume that all these companies (even if successful in trials) will make it to market and commercial success. The upside for us is that we really don't need that many of them to do it. We have had one excellent and very lucrative result with Novartis. Another is pending. Something eventually around 5 of these long term commercial support contracts and OXB shareholders will be very pleased - especially when coupled with all our other non CAR-T prospects like CF. Not so great for the shareholders of the partners who don't make it though (which will be the majority because there are a huge number of bios chasing CAR-T, which of course has a finite number of targets & patients). Non CAR-T I really quite like the look of GeoVax at the moment (another OXB partner and long time battered stock) for a bit of a punt, because those vaccines will be worth a lot of money if it all works out in any one area. Countering this though is my c30 year experience in bios and remembering that whilst they all had really exciting prospects, only a tiny number actually crossed the finishing line. So, at the moment I'm very pleased with OXB as a service provider to that "whole" industry and (as you will have worked out) I'm also pretty convinced that one of our major shareholders is so sold on the same idea that I think they are about to make it a much bigger business. |
Posted at 24/11/2024 21:04 by harry s truman takeiteasy,I'm guessing and it's nothing more than a theory which seems to me to fit quite well. Remember the only real news OXB have given us this year has been the upward revision of the guidance for FY25 and then news that we will be making a multiple myeloma CAR-T vector for somebody soon. Odds are that the next OXB news will be more detail on that. However, in the background here we have OXB's silent running and the possible simple coincidence that no OXB insiders have bought shares since Novo Holdings (the major OXB shareholder) bid for Catalent (huge CDMO which has a 4 / 5 plant C> division). My guess here is that Novo (who officially are only buying 50 location Catalent to get 3 sites to sell to Nordisk for their weight loss drugs) have a little side plan here to combine OXB with the Catalent C> division. It would roll out OXB's industry leading tech (I realise I'm biased as a holder but it is) into a capacity / capability which would be unaffordable for us near term, but for Novo could potentially give them a lion's share of a market forecast for C> which is huge. So what are the possibilities? 1) it's a complete coincidence and means nothing. 2) it's related to the Novo Holdings boss saying that they intend to use their windfall from the weight loss drugs to buy up speciality service companies. 3) it's something else. What are the answers? (aka my guesses) 1) nothing will happen with Novo and we will move into our return to profit in 2025 with a great year for shareholders. 2) Novo will make an offer for OXB (likely a friendly offer to placate IM and Serum) and create the No.1 C> CDMO in the world. With OXB's expertise, Novo's money and Catalent's waiting capacity then that's definitely on the cards there if they want to do it. 3) Could be something other than an offer for all of OXB but still linking the businesses. We will see in time, but Novo and Catalent both see this as being cleared before the end of the year and if there is a plan involving OXB subject to that approval then what would be the point in waiting? |
Posted at 19/11/2024 19:31 by takeiteasy some serious consolidation here across the sector even now hitting the "big 2" GLP1 plays - so everything is relative as they say, even our OXB share price :) |
Posted at 26/10/2024 08:23 by steeplejack The FT250 table included by philh75 is a very functional list that can be adjusted online by market cap.As things stand Tritax and Henderson Europe are currently occupying the important 325th position that is necessary to gain promotion to the FT250 and they both have a market cap in the mid £570m region.OXB has 105,36m shares in issue so-as a rule of thumb-a price of around 546p would suggest OXB would currently be promoted.There's a month to go to the next review but what is striking is the recent momentum in the OXB share price and the fact that studies show that shares invariably move sharply ahead of inclusion in an index,presumably as trackers buy in anticipation.Ceres did just that ahead on the most recent review but has fallen sharply thereafter and now has a market cap below OXB. |
Posted at 23/10/2024 18:43 by harry s truman This skyrocketing growth stock is up 100% this year! Is it too late to buy?Mark David Hartley Wed 23 October 2024 at 4:33 pm BST 3 min read Move aside Rolls-Royce and Fresnillo — this small-cap biotech share is skyrocketing past some of the UK’s leading growth stocks. Up 100% this year, OXB (LSE: OXB) is taking no prisoners as it fights to recover its losses from 2022. Between November 2021 and October 2022, the share price crashed 78%, falling from a high of £16.78 to almost £3 per share. The price continued to fall through 2023 but has now recovered to £4.18 — the highest it’s been in over a year. So what’s next for the stock? Cutting-edge biotechnology Previously known as Oxford Biomedica, OXB is a relatively small £442m stock listed on the FTSE All-Share index. The Oxford-based biopharmaceutical company focuses on cell and gene therapy, specialising in viral vector manufacturing. It has over 25 years of experience working with some of the leading pharmaceutical and biotech firms globally. Recently it shifted to a pure-play contract development and manufacturing organisation (CDMO), aiming to position itself as a leader in viral vector services, helping other firms develop and commercialise gene therapies. Over the past year, its portfolio grew to include 37 clients and 48 programmes, focusing on viral vector types like lentivirus and adeno-associated virus (AAV). The value of these contracts is approximately £94m as of 31 August. Shaky financials Last year was not kind to OXB, with the share price falling 50%. In the first half of 2023, it reported a 33% drop in revenues compared to the same period in 2022. The decline was primarily due to the non-recurrence of AstraZeneca Covid vaccine manufacturing. It also posted an operating EBITDA loss of £33.7m, higher than the £5.8m loss in the previous year. This was attributed to inflation combined with higher expenses related to its new Oxford Biomedica Solutions division. Things seem to be improving in 2024, although first-half earnings were still somewhat disappointing. Both revenue and earnings per share (EPS) missed analyst expectations, by 4.7% and 110%, respectively. Although it posted a net loss of £32.5m, this was a 32% improvement on H1 2023. The balance sheet looks okay for now, with a debt-to-equity ratio of 55.8%. However, it’s burning through cash and piling on debt, possibly due to increased operational expenses and rising bioprocessing costs. Cash and liquidity are key areas to watch as the company expects to break even in EBITDA by the end of 2024. In an announcement made in September during the rebranding to OXB, new CEO Dr. Frank Mathias said it aims to improve its financial standing by focusing on its role as a CDMO. It’s unclear how well the change to a CDMO will pay off, but the price is already reacting positively. However, the loss of a large client like Novartis could easily turn things around. It already faces tough competition in the CDMO market — any drop in performance could result in lost contracts. If things go well, the transition should provide more stable, long-term revenue as opposed to the volatile revenues from internal R&D. I expect it will continue to do well so if I weren’t already a shareholder, I’d happily buy the stock today. The post This skyrocketing growth stock is up 100% this year! Is it too late to buy? appeared first on The Motley Fool UK. Mark Hartley has positions in OXB. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2024 |
Posted at 22/10/2024 09:38 by harry s truman I share your cautious optimism Phil. Normally timing goes against OXB (because we are just lucky like that), but anticipation of inclusion back into the MSCI would seem to be ideally timed to help with the FTSE250 goal.A couple of cautions:- I've read the MSCI inclusion policy doc just now and it's as clear as mud to me, unlike the FTSE250 quarterly review which is simply market cap of 325th place or higher on the review date close. Anecdotally we do know that in the MSCI August '23 review (roughly our current share price but remember we have more shares now so a higher market cap on the same share price) we were not deleted from the MSCI index, but by November '23 our market cap saw us booted. Assuming (always dangerous I know) that there isn't a large gap between the addition market cap and the deletion market cap, then I'm quietly hopeful that OXB will be back in the MSCI this coming review. It would also explain quite well our recent share price movement on apparently no news. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
